Autologous Dendritic Cell Vaccine in Kidney Cancer

Phase 2 Recruiting 42 enrolled Jodi Maranchie

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to estimate the probability of immune response for the combination treatment of dendritic cell vaccine with oral cabozantinib and characterize the safety profile of interventional therapy.

Timeline

Start: 2023-07-06
Primary completion: 2027-12
Completion: 2027-12

Publications

Background Tannir NM, Pal SK, Atkins MB. Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review. Oncologist. 2018 May;23(5):540-555. doi: 10.1634/theoncologist.2017-0534. Epub 2018 Feb 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Autologous alpha-DC1/TBVA vaccine	Vaccine	—	Other
Subject	Cabozantinib	Small molecule	20 mg	Oral

Autologous Dendritic Cell Vaccine in Kidney Cancer

Summary

Timeline

Publications

Drugs

Indications